Personalized adjuvant therapies: Lessons from the past

摘要: For several decades, personalized adjuvant therapies have been prescribed based on features that predict response to specific types of treatment. In this summary four issues regarding are described. Each one developed using information from past experience and is ready be challenged by future findings clinical trials maturation follow-up data. 1) Accuracy determination steroid hormone receptors HER2-status was the key feature in International Breast Cancer Study Group (IBCSG) (BIG) trials. 2) Investigations ovarian function suppression IBCSG led design two (SOFT TEXT), which likely lead improved therapy for premenopausal women with breast cancer. 3) Data BIG 1-98 trial letrozole vs tamoxifen postmenopausal patients endocrine-responsive cancer provided might obtain increased benefit aromatase inhibitors achieve similar treatment outcome alone. 4) Finally, low-dose, frequently administered cytotoxics (metronomic chemotherapy) were tested advanced disease surprisingly favorable control very low incidence side effects. Personalized treatments improve substantially increasingly accurate their targets risk- toxicity-modulated therapies.